Lerodalcibep - LIB Therapeutics
Alternative Names: HST 101; LeroChol; LIB-003Latest Information Update: 14 Feb 2025
At a glance
- Originator LIB Therapeutics
- Developer Hasten Biopharmaceutic; LIB Therapeutics
- Class Antihyperlipidaemics; Recombinant fusion proteins
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Hypercholesterolaemia